Form 8-K - Current report:
SEC Accession No. 0001193125-25-113291
Filing Date
2025-05-06
Accepted
2025-05-06 07:28:38
Documents
15
Period of Report
2025-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d937417d8k.htm   iXBRL 8-K 25507
2 EX-99.1 d937417dex991.htm EX-99.1 64520
6 GRAPHIC g937417g0505202436863.jpg GRAPHIC 2721
  Complete submission text file 0001193125-25-113291.txt   231172

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20250506.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20250506_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20250506_pre.xml EX-101.PRE 11265
18 EXTRACTED XBRL INSTANCE DOCUMENT d937417d8k_htm.xml XML 3670
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 25915239
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)